| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| ProKidney Corp. | REGEN-016 - (PROACT 2) | Type 2 Diabetes | Phase 3 | Trial Discontinued | Intravenous | Endocrinology |
| ProKidney Corp. | Rilparencel - (REGEN-007) | Diabetic CKD Stage 3/4 | Phase 2 | Data Released | Oral | Endocrinology |
| ProKidney Corp. | RMCL-002 - (REACT) | Type 2 diabetes, prevent/delay CKD | Phase 2 | Data Released | Intravenous | Endocrinology |
| ProKidney Corp. | REGEN-003 | Type 2 Diabetes | Phase 2 | Trial Completed | Intravenous | Endocrinology |
| ProQR Therapeutics N.V. | QR-421a - (Sirius) | Retinitis Pigmentosa | Phase 2/3 | Trial Discontinued | Intravitreal injection | Genetic Disorder |
| ProQR Therapeutics N.V. | QR-421a - (Celeste) | Usher Syndrome Type 2 | Phase 2/3 | Ongoing | Intravitreal | Genetic Disorder |
| ProQR Therapeutics N.V. | Sepofarsen (QR-110) - (ILLUMINATE) | Leber's Congenital Amaurosis (LCA) - Genetic blindness | Phase 2/3 | Trial Discontinued | Intravitreal injection | Genetic Disorder |
| ProQR Therapeutics N.V. | QR-421a - (Helia) | Retinitis pigmentosa | Phase 2 | Trial Discontinued | Intravitreal injection | Genetic Disorder |